InsidersTradesSigma
Track the Hyperfine, Inc. share price and the full management transaction log of the company, a listed issuer based in United States. Shares are listed on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Hyperfine, Inc. has logged 66 reports. Market capitalisation: €90.9m. The latest transaction was disclosed on 25 August 2026 (Cession). Among the most active insiders: TEISSEYRE THOMAS. The full history is free.
66
Insider Decl.
n/a
Thresholds
€2m
11 ops.
Buy Volume
€246,230
28 ops.
Sell Volume
39Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 26,395 of 29,062 companies
21.0
score / 100
Value6
Quality36
FCF yld-33%
Earn yld-40%
EV/EBITDA·
ROE-97%
Gross mgn50%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 25 August 2026
Declarations66 total
7,345 shares@ US$0.854Class A Common StockSEC:0001193125-26-365144:0
7,345 shares@ US$0.854Class A Common StockSEC:0001193125-26-365147:0
330,000 shares0Class A Common StockSEC:0001193125-26-138149:0
750,000 shares0Class A Common StockSEC:0001193125-26-138139:0
330,000 shares0Class A Common StockSEC:0001193125-26-138144:0
24,188 shares@ US$1.2147.7% of flowClass A Common StockSEC:0001193125-26-124368:0
24,188 shares@ US$1.21100.0% of flowClass A Common StockSEC:0001193125-26-124362:0
821 shares@ US$1.11151.4% of flowClass A Common StockSEC:0001193125-26-054433:0
1,405 shares@ US$1.082.4% of flowClass A Common StockSEC:0001193125-25-288507:0
1,151 shares@ US$1.332.4% of flowClass A Common StockSEC:0000950170-25-109724:0
300,000 shares0Class A Common StockSEC:0000950170-25-075386:0
300,000 shares0Class A Common StockSEC:0000950170-25-075380:0
2,776 shares@ US$0.585.2% of flowClass A Common StockSEC:0000950170-25-073807:0
3,238 shares@ US$1.0812.1% of flowClass A Common StockSEC:0000950170-25-024316:0
3,237 shares@ US$1.2013.3% of flowClass A Common StockSEC:0000950170-25-022627:0
2,800 shares@ US$0.858.1% of flowClass A Common StockSEC:0000950170-24-128110:0
2,746 shares@ US$1.059.4% of flowClass A Common StockSEC:0000950170-24-098132:0
2,753 shares@ US$0.888.0% of flowClass A Common StockSEC:0001209191-24-005657:0
3,230 shares@ US$1.1112.0% of flowClass A Common StockSEC:0001209191-24-003440:0
2,655 shares@ US$1.2611.1% of flowClass A Common StockSEC:0001209191-23-055911:0
2,785 shares@ US$2.2620.8% of flowClass A Common StockSEC:0001209191-23-046315:0
1,729 shares@ US$2.263.4% of flowClass A Common StockSEC:0001209191-23-046313:0
1,735 shares@ US$1.251.9% of flowClass A Common StockSEC:0001209191-23-029926:0
4,635 shares@ US$1.395.6% of flowClass A Common StockSEC:0001209191-23-010632:0
5,613 shares@ US$1.3933.5% of flowClass A Common StockSEC:0001209191-23-010623:0
25 of 66 declarations
关于 Hyperfine, Inc.
Hyperfine, Inc. (纳斯达克: HYPR) 是一家总部位于美国康涅狄格州吉尔福德的医疗技术公司，专注于便携式、超低场脑部成像。该公司开发并商业化 Swoop® 平台，该平台被其描述为首个获得 FDA 批准用于脑部成像的便携式 MRI 系统。对于法国、比利时和瑞士的投资者而言，Hyperfine 处于数字健康、诊断成像和即时护理交付的交汇点，其主张围绕可及性、便携性以及将脑部 MRI 更贴近患者的能力。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001833769/000119312526114044/hypr-20251231.htm?utm_source=openai)) Hyperfine 由 Jonathan Rothberg 博士于 2014 年在技术孵化器 4Catalyzer 内部创立。公司的起源故事与应用成像工程领域的创新以及使 MRI 更易于获取和负担得起的使命紧密相连。Hyperfine 后来成为一家上市公司，并在纳斯达克上市，其 A 类普通股以 HYPR 为代码交易。其监管历史一直是投资案例的核心：公司于 2020 年获得了 Swoop 系统的初始 FDA 510(k) 批准，此后继续增加额外的批准和软件升级。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001833769/000119312526114044/hypr-20251231.htm?utm_source=openai)) 该业务以 Swoop 系统及相关软件和服务产品为中心，最值得注意的是 Optive AI™ 软件套件。这些产品旨在提高图像质量、临床工作流程和诊断效用，同时支持在传统 MRI 难以部署的护理场所使用。Hyperfine 的商业策略目标是医院、急诊科、神经内科诊所和国际市场，将公司定位为传统 MRI 供应商的差异化替代品，而非直接替代。其竞争优势在于便携性、较低的基础设施要求以及在护理点进行成像的能力。([investors.hyperfine.io](https://investors.hyperfine.io/news-releases/news-release-details/hyperfine-announces-fda-clearance-optive-aitm-software/?utm_source=openai)) 从地理上看，Hyperfine 仍主要以美国为中心，核心业务在康涅狄格州，更广泛的商业和开发足迹也包括加利福尼亚州。与此同时，管理层一直在明确表示国际扩张。2025 年和 2026 年，公司获得了下一代 Swoop 系统和 Optive AI 软件的 CE 和 UKCA 标志，从而进入欧洲经济区和英国市场。公司还披露了在英国和欧洲的少量员工，表明其海外业务的初步发展。([sec.gov](https://www.sec.gov/Archives/edgar/data/0001833769/000119312526114044/hypr-20251231.htm?utm_source=openai)) 近期里程碑至关重要。2025 年，Hyperfine 宣布其由 Optive AI 驱动的下一代 Swoop 系统获得 FDA 批准，随后该系统首次商业销售给美国医院。2026 年初，管理层强调了在医院、神经内科诊所和国际渠道的势头，同时还展示了与中风检测和神经内科用例相关的临床数据。因此，投资叙事仍然是一个经典的医疗技术商业化故事：一方面是专有技术、不断扩大的临床证据和监管进展，另一方面是执行风险、报销复杂性以及将创新转化为持续收入增长的需求。([investors.hyperfine.io](https://investors.hyperfine.io/news-releases/news-release-details/hyperfine-announces-fda-clearance-new-next-generation-swoopr?utm_source=openai))
